Erythropoietin, Modified to Not Stimulate Red Blood Cell Production, Retains Its Cardioprotective Properties
Authors:
- Melissa KrawczykMKMelissa Krawczyk
- Doojin PaikDPDoojin Paik
- Thomas ColemanTCThomas Coleman
- Michael BrinesMBMichael Brines
- Magdalena JuhaszovaMJMagdalena Juhaszova
- Steven J. SollottSSSteven J. Sollott
- Edward G. LakattaELEdward G. Lakatta
- Mark I. TalanMTMark I. Talan
Open Access
- 1 March 2006
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 316 (3) , 999-1005
Abstract
Erythropoietin (EPO), a hematopoietic cytokine, possesses strong antiapoptotic, tissue-protective properties. For clinical applications, it is desirable to separate the hematopoietic and tissue-protective properties. Recently introduced carbamylated erythropoietin (CEPO) does not stimulate the erythropoiesis but retains the antiapoptotic and neuroprotective effects. We tested the ability of CEPO to protect cardiac tissue from toxin-induced and oxidative stress in vitro and ischemic damage in vivo and compared these effects with the effects of EPO. CEPO reduced by 50% the extent of staurosporine-induced apoptosis in isolated rats' cardiomyocytes and increased by 25% the reactive oxygen species threshold for induction of the mitochondrial permeability transition. In an experimental model of myocardial infarction induced by permanent ligation of a coronary artery in rats, similarly to EPO, a single bolus injection of 30 μg/kg b.wt. of CEPO immediately after coronary ligation reduced apoptosis in the myocardial area at risk, examined 24 h later, by 50%. Left ventricular remodeling (ventricular dilation) and functional decline (fall in ejection fraction) assessed by repeated echocardiography were significantly and similarly attenuated in CEPO- and EPO-treated rats. Four weeks after coronary ligation, the myocardial infarction (MI) size in CEPO- and EPO-treated rats was half of that in untreated coronary-ligated animals. Unlike EPO, CEPO had no effect on hematocrit. The antiapoptotic cardioprotective effects of CEPO, shown by its ability to limit both post-MI left ventricular remodeling and the extent of the myocardial scar in the model of permanent coronary artery ligation in rats, demonstrate comparable potency to that of native (nonmodified) EPO.Keywords
This publication has 25 references indexed in Scilit:
- A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia–reperfusion injuryProceedings of the National Academy of Sciences, 2005
- New Avenues of Exploration for ErythropoietinJAMA, 2005
- Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptorProceedings of the National Academy of Sciences, 2004
- An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotectionCardiovascular Research, 2004
- Erythropoietin as an antiapoptotic, tissue-protective cytokineCell Death & Differentiation, 2004
- Derivatives of Erythropoietin That Are Tissue Protective But Not ErythropoieticScience, 2004
- Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodelingProceedings of the National Academy of Sciences, 2003
- A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in MiceJournal of Cerebral Blood Flow & Metabolism, 1999
- Myocyte apoptosis during acute myocardial infarction in the mouse localizes to hypoxic regions but occurs independently of p53.Journal of Clinical Investigation, 1997
- Single adult rabbit and rat cardiac myocytes retain the Ca2+- and species-dependent systolic and diastolic contractile properties of intact muscle.Journal of General Physiology, 1986